ONCY · Oncolytics Biotech Inc

-

Please sign in to comment on ONCY

1 Comment

Admin

4 years, 1 month ago

Oncolytics Biotech Inc is currently in a long term downtrend where the price is trading 4.1% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Oncolytics Biotech Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 51.9% to $-9M since the same quarter in the previous year.

Finally, its free cash flow grew by 21.0% to $-6M since the same quarter in the previous year.

Based on the above factors, Oncolytics Biotech Inc gets an overall score of 3/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	CA6823108759
Sector	Healthcare
Industry	Biotechnology

Market Cap	48M
PE Ratio	None
Beta	1.55
Target Price	4.157
Dividend Yield	None

ABOUT

Oncolytics Biotech Inc

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

ONCY · Oncolytics Biotech Inc

-

Oncolytics Biotech Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Oncolytics Biotech Inc using a moving average strategy